Rifampin

Rifampin Manufacturers

• State Of Florida Doh Central Pharmacy
  

  ×

  Rifampin | State Of Florida Doh Central Pharmacy

  

  ---

  Rifampin can be administered by the oral route or by IV infusion (see INDICATIONS AND USAGE). IV doses are the same as those for oral. See CLINICAL PHARMACOLOGY for dosing information in patients with renal failure.

  Tuberculosis

  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day.

  Pediatric Patients: 10 to 20 mg/kg, not to exceed 600 mg/day.

  It is recommended that rifampin be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.

  Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.

  Following the initial phase, treatment should be continued with rifampin and isoniazid for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.

  Meningococcal Carriers

  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.

  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.

  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.

  Preparation of Extemporaneous Oral Suspension

  For pediatric and adult patients in whom capsule swallowing is difficult or where lower doses are needed, a liquid suspension may be prepared as follows:

  Rifampin 1% w/v suspension (10 mg/mL) can be compounded using Simple Syrup (Syrup NF).

  Empty the contents of four Rifampin 300 mg capsules or eight Rifampin 150 mg capsules onto a piece of weighing paper. If necessary, gently crush the capsule contents with a spatula to produce a fine powder. Transfer the rifampin powder blend to a 4-ounce amber glass or plastic (high density polyethylene [HDPE], polypropylene, or polycarbonate) prescription bottle. Rinse the paper and spatula with 20 mL of syrup, and add the rinse to the bottle. Shake vigorously. Add 100 mL of the syrup to the bottle and shake vigorously.

  This compounding procedure results in a 1% w/v suspension containing 10 mg rifampin/mL. Stability studies indicate that the suspension is stable when stored at room temperature (25 ± 3° C) or in a refrigerator (2-8° C) for four weeks. This extemporaneously prepared suspension must be shaken well prior to administration.

  Close
  No Recall

  More Info
• Remedyrepack Inc.
  

  ×

  Rifampin | Remedyrepack Inc.

  

  ---

  Rifampin can be administered by the oral route (see INDICATIONS AND USAGE). See CLINICAL PHARMACOLOGYfor dosing information in patients with renal failure.
  
  Tuberculosis
  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, orally.
  Pediatric Patients: 10 to 20 mg/kg, not to exceed 600 mg/day, orally.
  It is recommended that oral rifampin capsule be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.
  Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.
  Following the initial phase, treatment should be continued with rifampin and isoniazid for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.
  
  Incompatibilities:
  Physical incompatibility (precipitate) was observed with undiluted (5 mg/mL) and diluted (1 mg/mL in normal saline) diltiazem hydrochloride and rifampin (6 mg/mL in normal saline) during simulated Y-site administration.
  
  Meningococcal Carriers
  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.
  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.
  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.
  
  Preparation of Extemporaneous Oral Suspension
  For pediatric and adult patients in whom capsule swallowing is difficult or where lower doses are needed, a liquid suspension may be prepared as follows:
  Rifampin 1% w/v suspension (10 mg/mL) can be compounded using one of four syrups-Simple Syrup (Syrup NF), Simple Syrup (Humco Laboratories) Syrpalta Syrup (Emerson Laboratories) or Raspberry Syrup (Humco Laboratories).
  1. Empty the contents of four Rifampin 300 mg capsules or eight Rifampin 150 mg capsules onto a piece of weighing paper.
  2. If necessary, gently crush the capsule contents with a spatula to produce a fine powder.
  3. Transfer the rifampin powder blend to a 4-ounce amber glass or plastic (high density polyethylene [HDPE], polypropylene, or polycarbonate) prescription bottle.
  4. Rinse the paper and spatula with 20 mL of syrup, and add the rinse to the bottle. Shake vigorously.
  5. Add 100 mL of syrup to the bottle and shake vigorously.
  This compounding procedure results in a 1% w/v suspension containing 10 mg rifampin/mL. Stability studies indicate that the suspension is stable when stored at room temperature (253C) or in a refrigerator (2-8C) for four weeks. This extemporaneously prepared suspension must be shaken well prior to administration.
  
  

  Close
  No Recall

  More Info
• Remedyrepack Inc.
  

  ×

  Rifampin | Remedyrepack Inc.

  

  ---

  Rifampin can be administered by the oral route (see INDICATIONS AND USAGE). See CLINICAL PHARMACOLOGYfor dosing information in patients with renal failure.
  
  Tuberculosis
  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, orally.
  Pediatric Patients: 10 to 20 mg/kg, not to exceed 600 mg/day, orally.
  It is recommended that oral rifampin capsule be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.
  Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.
  Following the initial phase, treatment should be continued with rifampin and isoniazid for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.
  
  Incompatibilities:
  Physical incompatibility (precipitate) was observed with undiluted (5 mg/mL) and diluted (1 mg/mL in normal saline) diltiazem hydrochloride and rifampin (6 mg/mL in normal saline) during simulated Y-site administration.
  
  Meningococcal Carriers
  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.
  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.
  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.
  
  Preparation of Extemporaneous Oral Suspension
  For pediatric and adult patients in whom capsule swallowing is difficult or where lower doses are needed, a liquid suspension may be prepared as follows:
  Rifampin 1% w/v suspension (10 mg/mL) can be compounded using one of four syrups-Simple Syrup (Syrup NF), Simple Syrup (Humco Laboratories) Syrpalta Syrup (Emerson Laboratories) or Raspberry Syrup (Humco Laboratories).
  1. Empty the contents of four Rifampin 300 mg capsules or eight Rifampin 150 mg capsules onto a piece of weighing paper.
  2. If necessary, gently crush the capsule contents with a spatula to produce a fine powder.
  3. Transfer the rifampin powder blend to a 4-ounce amber glass or plastic (high density polyethylene [HDPE], polypropylene, or polycarbonate) prescription bottle.
  4. Rinse the paper and spatula with 20 mL of syrup, and add the rinse to the bottle. Shake vigorously.
  5. Add 100 mL of syrup to the bottle and shake vigorously.
  This compounding procedure results in a 1% w/v suspension containing 10 mg rifampin/mL. Stability studies indicate that the suspension is stable when stored at room temperature (253C) or in a refrigerator (2-8C) for four weeks. This extemporaneously prepared suspension must be shaken well prior to administration.
  
  

  Close
  No Recall

  More Info
• Rebel Distributors Corp
  

  ×

  Rifampin | Rebel Distributors Corp

  

  ---

  Rifampin can be administered by the oral route (see INDICATIONS AND USAGE). See CLINICAL PHARMACOLOGY for dosing information in patients with renal failure.

  Tuberculosis

  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, orally.

  Pediatric Patients: 10 to 20 mg/kg, not to exceed 600 mg/day, orally.

  It is recommended that oral rifampin capsule be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.

  Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.

  Following the initial phase, treatment should be continued with rifampin and isoniazid for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.

  Incompatibilities:

  Physical incompatibility (precipitate) was observed with undiluted (5 mg/mL) and diluted (1 mg/mL in normal saline) diltiazem hydrochloride and rifampin (6 mg/mL in normal saline) during simulated Y-site administration.

  Meningococcal Carriers

  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.

  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.

  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.

  Preparation of Extemporaneous Oral Suspension

  For pediatric and adult patients in whom capsule swallowing is difficult or where lower doses are needed, a liquid suspension may be prepared as follows:

  Rifampin 1% w/v suspension (10 mg/mL) can be compounded using one of four syrups-Simple Syrup (Syrup NF), Simple Syrup (Humco Laboratories) Syrpalta Syrup (Emerson Laboratories) or Raspberry Syrup (Humco Laboratories).

  1. Empty the contents of four Rifampin 300 mg capsules or eight Rifampin 150 mg capsules onto a piece of weighing paper.

  2. If necessary, gently crush the capsule contents with a spatula to produce a fine powder.

  3. Transfer the rifampin powder blend to a 4-ounce amber glass or plastic (high density polyethylene [HDPE], polypropylene, or polycarbonate) prescription bottle.

  4. Rinse the paper and spatula with 20 mL of syrup, and add the rinse to the bottle. Shake vigorously.

  5. Add 100 mL of syrup to the bottle and shake vigorously.

  This compounding procedure results in a 1% w/v suspension containing 10 mg rifampin/mL. Stability studies indicate that the suspension is stable when stored at room temperature (25 ± 3° C) or in a refrigerator (2-8° C) for four weeks. This extemporaneously prepared suspension must be shaken well prior to administration.

  Close
  No Recall

  More Info
• Versapharm Incorporated
  

  ×

  Rifampin | Versapharm Incorporated

  

  ---

  Rifampin can be administered by the oral route (see INDICATIONS AND USAGE).

  See CLINICAL PHARMACOLOGY for dosing information in patients with renal failure.

  Tuberculosis

  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day.

  Pediatric Patients: 10-20 mg/kg, not to exceed 600 mg/day.

  It is recommended that oral rifampin be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.

  Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide [e.g., RIFATER®]5 is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.

  Following the initial phase, treatment should be continued with rifampin and isoniazid [RIFAMATE®]6. for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.

  Meningococcal Carriers

  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.

  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.

  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.

  Preparation of Extemporaneous Oral Suspension

  For pediatric and adult patients in whom capsule swallowing is difficult or where lower doses are needed, a liquid suspension may be prepared as follows:

  Rifampin 1% w/v suspension (10 mg/mL) can be compounded using Simple Syrup (Syrup NF):

  1. Empty the contents of four Rifampin 300 mg capsules or eight Rifampin 150 mg capsules onto a piece of weighing paper. 2. If necessary, gently crush the capsule contents with a spatula to produce a fine powder. 3. Transfer the rifampin powder blend to a 4-ounce amber glass or plastic (high density polyethylene [HDPE], polypropylene, or polycarbonate) prescription bottle. 4. Rinse the paper and spatula with 20 mL of syrup, and add the rinse to the bottle. Shake vigorously. 5. Add 100 mL of syrup to the bottle and shake vigorously.

  This compounding procedure results in a 1% w/v suspension containing 10 mg rifampin/mL. Stability studies indicate that the suspension is stable when stored at room temperature (25 ± 3°C) or in a refrigerator (2-8°C) for four weeks. This extemporaneously prepared suspension must be shaken well prior to administration.

  Close
  No Recall

  More Info
• Remedyrepack Inc.
  

  ×

  Rifampin | Remedyrepack Inc.

  

  ---

  Rifampin can be administered by the oral route (see INDICATIONS AND USAGE). See CLINICAL PHARMACOLOGYfor dosing information in patients with renal failure.
  
  Tuberculosis
  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, orally.
  Pediatric Patients: 10 to 20 mg/kg, not to exceed 600 mg/day, orally.
  It is recommended that oral rifampin capsule be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.
  Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., RIFATERis recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.
  Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATEfor at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.
  
  Incompatibilities:
  Physical incompatibility (precipitate) was observed with undiluted (5 mg/mL) and diluted (1 mg/mL in normal saline) diltiazem hydrochloride and rifampin (6 mg/mL in normal saline) during simulated Y-site administration.
  
  Meningococcal Carriers
  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.
  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.
  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.
  
  Preparation of Extemporaneous Oral Suspension
  For pediatric and adult patients in whom capsule swallowing is difficult or where lower doses are needed, a liquid suspension may be prepared as follows:
  Rifampin 1% w/v suspension (10 mg/mL) can be compounded using one of four syrups-Simple Syrup (Syrup NF), Simple Syrup (Humco Laboratories) Syrpalta Syrup (Emerson Laboratories) or Raspberry Syrup (Humco Laboratories).
  1. Empty the contents of four Rifampin 300 mg capsules or eight Rifampin 150 mg capsules onto a piece of weighing paper.
  2. If necessary, gently crush the capsule contents with a spatula to produce a fine powder.
  3. Transfer the rifampin powder blend to a 4-ounce amber glass or plastic (high density polyethylene [HDPE], polypropylene, or polycarbonate) prescription bottle.
  4. Rinse the paper and spatula with 20 mL of one of the above mentioned syrups, and add the rinse to the bottle. Shake vigorously.
  5. Add 100 mL of syrup to the bottle and shake vigorously.
  This compounding procedure results in a 1% w/v suspension containing 10 mg rifampin/mL. Stability studies indicate that the suspension is stable when stored at room temperature (253C) or in a refrigerator (2 to 8C) for four weeks. This extemporaneously prepared suspension must be shaken well prior to administration.
  
  

  Close
  No Recall

  More Info
• Physicians Total Care, Inc.
  

  ×

  Rifampin | Physicians Total Care, Inc.

  

  ---

  Rifampin can be administered by the oral route (see INDICATIONS AND USAGE).

  See CLINICAL PHARMACOLOGY for dosing information in patients with renal failure.

  Tuberculosis

  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, oral

  Pediatric Patients: 10-20 mg/kg, not to exceed 600 mg/day, oral

  It is recommended that oral rifampin be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.

  Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., RIFATER®1) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.

  Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE®2) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.

  Meningococcal Carriers

  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.

  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.

  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.

  Close
  No Recall

  More Info
• H.j. Harkins Company, Inc.
  

  ×

  Rifampin | H.j. Harkins Company, Inc.

  

  ---

  Rifampin can be administered by the oral route (see INDICATIONS AND USAGE).

  See CLINICAL PHARMACOLOGY for dosing information in patients with renal failure.

  Tuberculosis

  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day.

  Pediatric Patients: 10-20 mg/kg, not to exceed 600 mg/day.

  It is recommended that oral rifampin be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.

  Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen
  consisting of rifampin, isoniazid, and pyrazinamide (RIFATER® manufactured by sanofi-aventisU.S. LLC) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.

  Following the initial phase, treatment should be continued with rifampin and isoniazid (RIFAMATE® manufactured by sanofi-aventis U.S. LLC) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.

  Meningococcal Carriers

  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.

  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.

  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.

  Preparation of Extemporaneous Oral Suspension

  For pediatric and adult patients in whom capsule swallowing is difficult or where lower doses are needed, a liquid suspension may be prepared as follows:

  Rifampin 1% w/v suspension (10 mg/mL) can be compounded using Simple Syrup (Syrup NF):

  1. Empty the contents of four Rifampin 300 mg capsules or eight Rifampin 150 mg capsules onto a piece of weighing paper.

  2. If necessary, gently crush the capsule contents with a spatula to produce a fine powder.

  3. Transfer the rifampin powder blend to a 4-ounce amber glass or plastic (high density polyethylene [HDPE], polypropylene, or polycarbonate) prescription bottle.

  4. Rinse the paper and spatula with 20 mL of syrup, and add the rinse to the bottle. Shake vigorously.

  5. Add 100 mL of syrup to the bottle and shake vigorously.

  This compounding procedure results in a 1% w/v suspension containing 10 mg rifampin/mL. Stability studies indicate that the suspension is stable when stored at room temperature (25 ± 3°C) or in a refrigerator (2-8°C) for four weeks. This extemporaneously prepared suspension must be shaken well prior to administration.

  Close
  No Recall

  More Info
• Rebel Distributors Corp
  

  ×

  Rifampin | Rebel Distributors Corp

  

  ---

  Rifampin can be administered by the oral route (see INDICATIONS AND USAGE).

  See CLINICAL PHARMACOLOGY for dosing information in patients with renal failure.

  Tuberculosis

  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, oral

  Pediatric Patients: 10-20 mg/kg, not to exceed 600 mg/day, oral

  It is recommended that oral rifampin be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.

  Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., RIFATER®3) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.

  Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE®4) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.

  3

  RIFATER® (rifampin, isoniazid, and pyrazinamide) is a registered trademark of Sanofi-Aventis U.S.

  4

  RIFAMATE® (rifampin and isoniazid) is a registered trademark of Sanofi-Aventis U.S.

  Meningococcal Carriers

  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.

  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.

  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.

  Close
  No Recall

  More Info
• Akorn Inc.
  

  ×

  Rifampin | Neogen Corporation-mercer Rd

  

  ---

  ​DOSAGE:

  ​Horses: Adminsiter 2-3 oz (60-90 mL) orally every 2 hours or as needed for gastric reflux.

  Dogs: Administer 1-2 teaspoons (5-10 mL) orally every 4-6 hours (antacid).

            Administer 1-3 teaspoons (15-50 mL) orally once daily (laxative).

  EACH TEASPOON CONTAINS:

  Magnesium hydroxide 400 mg (80 mg/mL)

  ACTIVE INGREDIENTS:

  Magnesium hydroxide 8% (w/v)

  OTHER INGREDIENTS:

  Sodium hypochlorite, water

  Close
  No Recall

  More Info
• Bryant Ranch Prepack
  

  ×

  Rifampin | Bryant Ranch Prepack

  

  ---

  Rifampin can be administered by the oral route (see INDICATIONS AND USAGE). See CLINICAL PHARMACOLOGY for dosing information in patients with renal failure.

  Tuberculosis

  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, orally.

  Pediatric Patients: 10 to 20 mg/kg, not to exceed 600 mg/day, orally.

  It is recommended that oral rifampin capsule be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.

  Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.

  Following the initial phase, treatment should be continued with rifampin and isoniazid for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.

  Incompatibilities:

  Physical incompatibility (precipitate) was observed with undiluted (5 mg/mL) and diluted (1 mg/mL in normal saline) diltiazem hydrochloride and rifampin (6 mg/mL in normal saline) during simulated Y-site administration.

  Meningococcal Carriers

  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.

  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.

  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.

  Preparation of Extemporaneous Oral Suspension

  For pediatric and adult patients in whom capsule swallowing is difficult or where lower doses are needed, a liquid suspension may be prepared as follows:

  Rifampin 1% w/v suspension (10 mg/mL) can be compounded using one of four syrups-Simple Syrup (Syrup NF), Simple Syrup (Humco Laboratories) Syrpalta Syrup (Emerson Laboratories) or Raspberry Syrup (Humco Laboratories).

  1. Empty the contents of four Rifampin 300 mg capsules or eight Rifampin 150 mg capsules onto a piece of weighing paper.

  2. If necessary, gently crush the capsule contents with a spatula to produce a fine powder.

  3. Transfer the rifampin powder blend to a 4-ounce amber glass or plastic (high density polyethylene [HDPE], polypropylene, or polycarbonate) prescription bottle.

  4. Rinse the paper and spatula with 20 mL of syrup, and add the rinse to the bottle. Shake vigorously.

  5. Add 100 mL of syrup to the bottle and shake vigorously.

  This compounding procedure results in a 1% w/v suspension containing 10 mg rifampin/mL. Stability studies indicate that the suspension is stable when stored at room temperature (25 ± 3° C) or in a refrigerator (2-8° C) for four weeks. This extemporaneously prepared suspension must be shaken well prior to administration.

  Close
  No Recall

  More Info
• Mylan Institutional Inc.
  

  ×

  Rifampin | Novartis Consumer Health, Inc.

  

  ---

  • do not use more than directed • take every 4 hours, while symptoms persist. Do not take more than 6 packets in 24 hours unless directed by a doctor   Age   Dose   adults and children 12 years of age and over   one packet   children under 12 years of age   do not use • dissolve contents of one packet into 8 oz. hot water; sip while hot. Consume entire drink within 10-15 minutes. • if using a microwave, add contents of one packet to 8 oz. of cool water; stir briskly before and after heating. Do not overheat.

  Close
  No Recall

  More Info
• Cardinal Health
  

  ×

  Rifampin | Cardinal Health

  

  ---

  Rifampin can be administered by the oral route (see INDICATIONS AND USAGE). See CLINICAL PHARMACOLOGY for dosing information in patients with renal failure.

  Tuberculosis

  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, orally.

  Pediatric Patients: 10 to 20 mg/kg, not to exceed 600 mg/day, orally.

  It is recommended that oral rifampin capsule be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.

  Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., RIFATER® (Sanofi-aventis U.S. LLC)) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.

  Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE® (Sanofi-aventis U.S. LLC)) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.

  Meningococcal Carriers

  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.

  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.

  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.

  Preparation of Extemporaneous Oral Suspension

  For pediatric and adult patients in whom capsule swallowing is difficult or where lower doses are needed, a liquid suspension may be prepared as follows:

  Rifampin 1% w/v suspension (10 mg/mL) can be compounded using one of four syrups-Simple Syrup (Syrup NF), Simple Syrup (Humco Laboratories) Syrpalta Syrup (Emerson Laboratories) or Raspberry Syrup (Humco Laboratories).

  1. Empty the contents of four Rifampin 300 mg capsules or eight Rifampin 150 mg capsules onto a piece of weighing paper.

  2. If necessary, gently crush the capsule contents with a spatula to produce a fine powder.

  3. Transfer the rifampin powder blend to a 4-ounce amber glass or plastic (high density polyethylene [HDPE], polypropylene, or polycarbonate) prescription bottle.

  4. Rinse the paper and spatula with 20 mL of one of the above mentioned syrups, and add the rinse to the bottle. Shake vigorously.

  5. Add 100 mL of syrup to the bottle and shake vigorously.

  This compounding procedure results in a 1% w/v suspension containing 10 mg rifampin/mL. Stability studies indicate that the suspension is stable when stored at room temperature (25 ± 3° C) or in a refrigerator (2 to 8° C) for four weeks. This extemporaneously prepared suspension must be shaken well prior to administration.

  Close
  No Recall

  More Info
• Cardinal Health
  

  ×

  Rifampin | Cardinal Health

  

  ---

  Rifampin can be administered by the oral route (see INDICATIONS AND USAGE).

  See CLINICAL PHARMACOLOGY for dosing information in patients with renal failure.

  Tuberculosis

  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day.

  Pediatric Patients: 10-20 mg/kg, not to exceed 600 mg/day.

  It is recommended that oral rifampin be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.

  Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen
  consisting of rifampin, isoniazid, and pyrazinamide (RIFATER® manufactured by sanofi-aventisU.S. LLC) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.

  Following the initial phase, treatment should be continued with rifampin and isoniazid (RIFAMATE® manufactured by sanofi-aventis U.S. LLC) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.

  Meningococcal Carriers

  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.

  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.

  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.

  Preparation of Extemporaneous Oral Suspension

  For pediatric and adult patients in whom capsule swallowing is difficult or where lower doses are needed, a liquid suspension may be prepared as follows:

  Rifampin 1% w/v suspension (10 mg/mL) can be compounded using Simple Syrup (Syrup NF):

  1. Empty the contents of four Rifampin 300 mg capsules or eight Rifampin 150 mg capsules onto a piece of weighing paper.

  2. If necessary, gently crush the capsule contents with a spatula to produce a fine powder.

  3. Transfer the rifampin powder blend to a 4-ounce amber glass or plastic (high density polyethylene [HDPE], polypropylene, or polycarbonate) prescription bottle.

  4. Rinse the paper and spatula with 20 mL of syrup, and add the rinse to the bottle. Shake vigorously.

  5. Add 100 mL of syrup to the bottle and shake vigorously.

  This compounding procedure results in a 1% w/v suspension containing 10 mg rifampin/mL. Stability studies indicate that the suspension is stable when stored at room temperature (25 ± 3°C) or in a refrigerator (2-8°C) for four weeks. This extemporaneously prepared suspension must be shaken well prior to administration.

  Close
  No Recall

  More Info
• Pfizer Laboratories Div Pfizer Inc
  

  ×

  Rifampin | Pfizer Laboratories Div Pfizer Inc

  

  ---

  Rifampin can be administered by IV infusion (see INDICATIONS AND USAGE).

  See CLINICAL PHARMACOLOGY for dosing information in patients with renal failure.

  Tuberculosis

  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, IV

  Pediatric Patients: 10–20 mg/kg, not to exceed 600 mg/day, IV

  Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., RIFATER® manufactured by Sanofi Aventis) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.

  Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE® manufactured by Sanofi Aventis) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.

  Preparation of Solution for IV Infusion

  Reconstitute the lyophilized powder by transferring 10 mL of sterile water for injection to a vial containing 600 mg of rifampin for injection. Swirl vial gently to completely dissolve the antibiotic. The reconstituted solution contains 60 mg rifampin per mL and is stable at room temperature for 24 hours. Prior to administration, withdraw from the reconstituted solution a volume equivalent to the amount of rifampin calculated to be administered and add to 500 mL of infusion medium. Mix well and infuse at a rate allowing for complete infusion within 3 hours. Alternatively, the amount of rifampin calculated to be administered may be added to 100 mL of infusion medium and infused in 30 minutes.

  Dilutions in dextrose 5% for injection (D5W) are stable at room temperature for up to 4 hours and should be prepared and used within this time. Precipitation of rifampin from the infusion solution may occur beyond this time. Dilutions in normal saline are stable at room temperature for up to 24 hours and should be prepared and used within this time. Other infusion solutions are not recommended.

  Incompatibilities

  Physical incompatibility (precipitate) was observed with undiluted (5 mg/mL) and diluted (1 mg/mL in normal saline) diltiazem hydrochloride and rifampin (6 mg/mL in normal saline) during simulated Y-site administration.

  Meningococcal Carriers

  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.

  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.

  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.

  Close
  No Recall

  More Info
• Pfizer Laboratories Div Pfizer Inc
  

  ×

  Rifampin | Pfizer Laboratories Div Pfizer Inc

  

  ---

  Rifampin can be administered by IV infusion (see INDICATIONS AND USAGE).

  See CLINICAL PHARMACOLOGY for dosing information in patients with renal failure.

  Tuberculosis

  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, IV

  Pediatric Patients: 10–20 mg/kg, not to exceed 600 mg/day, IV

  Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., RIFATER® manufactured by Sanofi Aventis) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.

  Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE® manufactured by Sanofi Aventis) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.

  Preparation of Solution for IV Infusion

  Reconstitute the lyophilized powder by transferring 10 mL of sterile water for injection to a vial containing 600 mg of rifampin for injection. Swirl vial gently to completely dissolve the antibiotic. The reconstituted solution contains 60 mg rifampin per mL and is stable at room temperature for 24 hours. Prior to administration, withdraw from the reconstituted solution a volume equivalent to the amount of rifampin calculated to be administered and add to 500 mL of infusion medium. Mix well and infuse at a rate allowing for complete infusion within 3 hours. Alternatively, the amount of rifampin calculated to be administered may be added to 100 mL of infusion medium and infused in 30 minutes.

  Dilutions in dextrose 5% for injection (D5W) are stable at room temperature for up to 4 hours and should be prepared and used within this time. Precipitation of rifampin from the infusion solution may occur beyond this time. Dilutions in normal saline are stable at room temperature for up to 24 hours and should be prepared and used within this time. Other infusion solutions are not recommended.

  Incompatibilities

  Physical incompatibility (precipitate) was observed with undiluted (5 mg/mL) and diluted (1 mg/mL in normal saline) diltiazem hydrochloride and rifampin (6 mg/mL in normal saline) during simulated Y-site administration.

  Meningococcal Carriers

  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.

  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.

  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.

  Close
  No Recall

  More Info
• Lannett Company, Inc.
  

  ×

  Rifampin | Lannett Company, Inc.

  

  ---

  Rifampin can be administered by the oral route (see INDICATIONS AND USAGE).

  See CLINICAL PHARMACOLOGY for dosing information in patients with renal failure.

  Tuberculosis

  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, oral

  Pediatric Patients: 10-20 mg/kg, not to exceed 600 mg/day, oral

  It is recommended that oral rifampin be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.

  Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., RIFATER®1) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.

  Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE®2) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.

  Meningococcal Carriers

  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.

  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.

  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.

  Close
  No Recall

  More Info
• Mckesson Packaging Services A Business Unit Of Mckesson Corporation
  

  ×

  Rifampin | Mckesson Packaging Services A Business Unit Of Mckesson Corporation

  

  ---

  Rifampin can be administered by the oral route (see INDICATIONS AND USAGE). See CLINICAL PHARMACOLOGY for dosing information in patients with renal failure.

  Tuberculosis

  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, orally.

  Pediatric Patients: 10 to 20 mg/kg, not to exceed 600 mg/day, orally.

  It is recommended that oral rifampin capsule be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.

  Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., RIFATER®) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.

  Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE®) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.

  Incompatibilities:

  Physical incompatibility (precipitate) was observed with undiluted (5 mg/mL) and diluted (1 mg/mL in normal saline) diltiazem hydrochloride and rifampin (6 mg/mL in normal saline) during simulated Y-site administration.

  Meningococcal Carriers

  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.

  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.

  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.

  Preparation of Extemporaneous Oral Suspension

  For pediatric and adult patients in whom capsule swallowing is difficult or where lower doses are needed, a liquid suspension may be prepared as follows:

  Rifampin 1% w/v suspension (10 mg/mL) can be compounded using one of four syrups-Simple Syrup (Syrup NF), Simple Syrup (Humco Laboratories) Syrpalta Syrup (Emerson Laboratories) or Raspberry Syrup (Humco Laboratories).

  1. Empty the contents of four Rifampin 300 mg capsules or eight Rifampin 150 mg capsules onto a piece of weighing paper.

  2. If necessary, gently crush the capsule contents with a spatula to produce a fine powder.

  3. Transfer the rifampin powder blend to a 4-ounce amber glass or plastic (high density polyethylene [HDPE], polypropylene, or polycarbonate) prescription bottle.

  4. Rinse the paper and spatula with 20 mL of one of the above mentioned syrups, and add the rinse to the bottle. Shake vigorously.

  5. Add 100 mL of syrup to the bottle and shake vigorously.

  This compounding procedure results in a 1% w/v suspension containing 10 mg rifampin/mL. Stability studies indicate that the suspension is stable when stored at room temperature (25 ± 3° C) or in a refrigerator (2 to 8° C) for four weeks. This extemporaneously prepared suspension must be shaken well prior to administration.

  Close
  No Recall

  More Info
• Remedyrepack Inc.
  

  ×

  Rifampin | Remedyrepack Inc.

  

  ---

  Rifampin can be administered by the oral route (see INDICATIONS AND USAGE).

  See CLINICAL PHARMACOLOGY for dosing information in patients with renal failure.

   

  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day.

  Pediatric Patients: 10-20 mg/kg, not to exceed 600 mg/day.

  It is recommended that oral rifampin be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.

  Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen
  consisting of rifampin, isoniazid, and pyrazinamide (RIFATER® manufactured by sanofi-aventisU.S. LLC) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.

  Following the initial phase, treatment should be continued with rifampin and isoniazid (RIFAMATE® manufactured by sanofi-aventis U.S. LLC) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.

   

  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.

  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.

  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.

   

  For pediatric and adult patients in whom capsule swallowing is difficult or where lower doses are needed, a liquid suspension may be prepared as follows:

  Rifampin 1% w/v suspension (10 mg/mL) can be compounded using Simple Syrup (Syrup NF):

  1. Empty the contents of four Rifampin 300 mg capsules or eight Rifampin 150 mg capsules onto a piece of weighing paper.

  2. If necessary, gently crush the capsule contents with a spatula to produce a fine powder.

  3. Transfer the rifampin powder blend to a 4-ounce amber glass or plastic (high density polyethylene [HDPE], polypropylene, or polycarbonate) prescription bottle.

  4. Rinse the paper and spatula with 20 mL of syrup, and add the rinse to the bottle. Shake vigorously.

  5. Add 100 mL of syrup to the bottle and shake vigorously.

  This compounding procedure results in a 1% w/v suspension containing 10 mg rifampin/mL. Stability studies indicate that the suspension is stable when stored at room temperature (25 ± 3°C) or in a refrigerator (2-8°C) for four weeks. This extemporaneously prepared suspension must be shaken well prior to administration.

   

  Close
  No Recall

  More Info
• Lupin Pharmaceuticals, Inc.
  

  ×

  Rifampin | Lupin Pharmaceuticals, Inc.

  

  ---

  Rifampin can be administered by the oral route (see INDICATIONS AND USAGE ). See CLINICAL PHARMACOLOGY for dosing information in patients with renal failure.

  Tuberculosis

  Adults

  10 mg/kg, in a single daily administration, not to exceed 600 mg/day, oral

  Pediatric Patients

  10-20 mg/kg, not to exceed 600 mg/day, oral

  It is recommended that oral rifampin be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.

  Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g. RIFATER®*) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial  treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.

  Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g. RIFAMATE®**) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.

  Meningococcal Carriers

  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.

  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.

  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.

  Preparation of Extemporaneous Oral Suspension

  For pediatric and adult patients in whom capsule swallowing is difficult or where lower doses are needed, a liquid suspension may be prepared as follows:

  Rifampin 1% w/v suspension (10 mg/mL) can be compounded using one of four syrups–Simple Syrup (Syrup NF), Simple Syrup (Humco Laboratories), Syrpalta®+ Syrup (Emerson Laboratories), or Raspberry Syrup (Humco Laboratories).

  Empty the contents of four rifampin capsules 300 mg or eight rifampin capsules 150 mg onto a piece of weighing paper. If necessary, gently crush the capsule contents with a spatula to produce a fine powder. Transfer the rifampin powder blend to a 4-ounce amber glass or plastic (high density polyethylene [HDPE], polypropylene, or polycarbonate) prescription bottle. Rinse the paper and spatula with 20 mL of one of the above-mentioned syrups, and add the rinse to the bottle. Shake vigorously. Add 100 mL of syrup to the bottle and shake vigorously.

  This compounding procedure results in a 1% w/v suspension containing 10 mg rifampin/mL. Stability studies indicate that the suspension is stable when stored at room temperature (25 ± 3°C) or in a refrigerator (2 to 8°C) for four weeks. This extemporaneously prepared suspension must be shaken well prior to administration.

  Close
  No Recall

  More Info
• Major Pharmaceuticals
  

  ×

  Rifampin | Major Pharmaceuticals

  

  ---

  Rifampin can be administered by the oral route (see INDICATIONS AND USAGE). See CLINICAL PHARMACOLOGY for dosing information in patients with renal failure.

  Tuberculosis

  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, oral

  Pediatric Patients: 10-20 mg/kg, not to exceed 600 mg/day, oral

  It is recommended that oral rifampin be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water. Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and

  pyrazinamide (e.g., RIFATER®1) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease

  Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.

  Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE®2) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.

  1RIFATER® (rifampin, isoniazid, and pyrazinamide) is a registered trademark of Sanofi-Aventis U.S. 2RIFAMATE® (rifampin and isoniazid) is a registered trademark of Sanofi-Aventis U.S.

  Meningococcal Carriers

  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.

  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days. Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.

  Close
  No Recall

  More Info
• Mylan Institutional Llc
  

  ×

  Rifampin | Mylan Institutional Llc

  

  ---

  Rifampin can be administered by IV infusion (see INDICATIONS AND USAGE).

  See CLINICAL PHARMACOLOGY for dosing information in patients with renal failure.

  Tuberculosis

  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, IV

  Pediatric Patients: 10-20 mg/kg, not to exceed 600 mg/day, IV

  Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.

  Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE® manufactured by Sanofi Aventis) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.

  Preparation of Solution for IV Infusion: Reconstitute the lyophilized powder by transferring 10 mL of sterile water for injection to a vial containing 600 mg of rifampin for injection. Swirl vial gently to completely dissolve the antibiotic. The reconstituted solution contains 60 mg rifampin per mL and is stable at room temperature for 24 hours. Prior to administration, withdraw from the reconstituted solution a volume equivalent to the amount of rifampin calculated to be administered and add to 500 mL of infusion medium. Mix well and infuse at a rate allowing for complete infusion within 3 hours. Alternatively, the amount of rifampin calculated to be administered may be added to 100 mL of infusion medium and infused in 30 minutes.

  Dilutions in dextrose 5% for injection (D5W) are stable at room temperature for up to 4 hours and should be prepared and used within this time. Precipitation of rifampin from the infusion solution may occur beyond this time. Dilutions in normal saline are stable at room temperature for up to 24 hours and should be prepared and used within this time. Other infusion solutions are not recommended.

  Incompatibilities: Physical incompatibility (precipitate) was observed with undiluted (5 mg/mL) and diluted (1 mg/mL in normal saline) diltiazem hydrochloride and rifampin (6 mg/mL in normal saline) during simulated Y-site administration.

  Meningococcal Carriers

  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.

  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.

  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.

  Close
  No Recall

  More Info
• American Health Packaging
  

  ×

  Rifampin | Pd-rx Pharmaceuticals, Inc.

  

  ---

  Levocetirizine is available as 5 mg breakable (scored) tablets, allowing for the administration of 2.5 mg, if needed. Levocetirizine dihydrochloride tablets can be taken without regard to food consumption.

  2.1 Adults and Children 12 Years of Age and Older

  The recommended dose of levocetirizine is 5 mg (1 tablet) once daily in the evening. Some patients may be adequately controlled by 2.5 mg (½ tablet) once daily in the evening.

  2.2 Children 6 to 11 Years of Age

  The recommended dose of levocetirizine is 2.5 mg (½ tablet) once daily in the evening. The 2.5 mg dose should not be exceeded because the systemic exposure with 5 mg is approximately twice that of adults [see Clinical Pharmacology (12.3)].

  2.3 Children 6 Months to 5 Years of Age

  The recommended initial dose of levocetirizine is 1.25 mg once daily in the evening. The 1.25 mg once daily dose should not be exceeded based on comparable exposure to adults receiving 5 mg [see Clinical Pharmacology ( 12.3) ].

  2.4 Dose Adjustment for Renal and Hepatic Impairment

  In adults and children 12 years of age and older with:

  Mild renal impairment (creatinine clearance [CL CR] = 50 to 80 mL/min): a dose of 2.5 mg once daily is recommended; Moderate renal impairment (CL CR = 30 to 50 mL/min): a dose of 2.5 mg once every other day is recommended; Severe renal impairment (CL CR = 10 to 30 mL/min): a dose of 2.5 mg twice weekly (administered once every 3 to 4 days) is recommended; End-stage renal disease patients (CL CR < 10 mL/min) and patients undergoing hemodialysis should not receive levocetirizine dihydrochloride tablets.

  No dose adjustment is needed in patients with solely hepatic impairment. In patients with both hepatic impairment and renal impairment, adjustment of the dose is recommended.

  Close
  No Recall

  More Info
• Eon Labs, Inc.
  

  ×

  Rifampin | Eon Labs, Inc.

  

  ---

  Rifampin can be administered by the oral route (see INDICATIONS AND USAGE). See CLINICAL PHARMACOLOGY for dosing information in patients with renal failure.

  Tuberculosis

  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, orally.

  Pediatric Patients: 10 to 20 mg/kg, not to exceed 600 mg/day, orally.

  It is recommended that oral rifampin capsule be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.

  Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., RIFATER® (Sanofi-aventis U.S. LLC)) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.

  Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE® (Sanofi-aventis U.S. LLC)) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.

  Meningococcal Carriers

  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.

  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.

  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.

  Preparation of Extemporaneous Oral Suspension

  For pediatric and adult patients in whom capsule swallowing is difficult or where lower doses are needed, a liquid suspension may be prepared as follows:

  Rifampin 1% w/v suspension (10 mg/mL) can be compounded using one of four syrups-Simple Syrup (Syrup NF), Simple Syrup (Humco Laboratories), Syrpalta® Syrup (Emerson Laboratories) or Raspberry Syrup (Humco Laboratories).

  1. Empty the contents of four Rifampin 300 mg capsules or eight Rifampin 150 mg capsules onto a piece of weighing paper. 2. If necessary, gently crush the capsule contents with a spatula to produce a fine powder. 3. Transfer the rifampin powder blend to a 4-ounce amber glass or plastic (high density polyethylene [HDPE], polypropylene, or polycarbonate) prescription bottle. 4. Rinse the paper and spatula with 20 mL of one of the above mentioned syrups, and add the rinse to the bottle. Shake vigorously. 5. Add 100 mL of syrup to the bottle and shake vigorously.

  This compounding procedure results in a 1% w/v suspension containing 10 mg rifampin/mL. Stability studies indicate that the suspension is stable when stored at room temperature (25 ± 3° C) or in a refrigerator (2 to 8° C) for four weeks. This extemporaneously prepared suspension must be shaken well prior to administration.

  Close
  No Recall

  More Info
• Bedford Laboratories
  

  ×

  Rifampin | Bedford Laboratories

  

  ---

  Rifampin for Injection is administered by IV infusion (see INDICATIONS AND USAGE).

  See CLINICAL PHARMACOLOGY for dosing information in patients with renal failure.

  Tuberculosis

  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, IV.

  Pediatric Patients: 10 to 20 mg/kg, not to exceed 600 mg/day, IV.

  Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., RIFATER®) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin, and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.

  Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE®) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.

  Preparation of Solution for IV Infusion

  Reconstitute the lyophilized powder by transferring 10 mL of sterile water for injection to a vial containing 600 mg of rifampin for injection. Swirl vial gently to completely dissolve the antibiotic. The reconstituted solution contains 60 mg rifampin per mL and is stable at room temperature for 24 hours. Prior to administration, withdraw from the reconstituted solution a volume equivalent to the amount of rifampin calculated to be administered and add to 500 mL of infusion medium. Mix well and infuse at a rate allowing for complete infusion within 3 hours. Alternatively, the amount of rifampin calculated to be administered may be added to 100 mL of infusion medium and infused in 30 minutes.

  Dilutions in dextrose 5% for injection (D5W) are stable at room temperature for up to 4 hours and should be prepared and used within this time. Precipitation of rifampin from the infusion solution may occur beyond this time. Dilutions in normal saline are stable at room temperature for up to 24 hours and should be prepared and used within this time. Other infusion solutions are not recommended.

  Incompatibilities

  Physical incompatibility (precipitate) was observed with undiluted (5 mg/mL) and diluted (1 mg/mL in normal saline) diltiazem hydrochloride and rifampin (6 mg/mL in normal saline) during simulated Y-site administration.

  Meningococcal Carriers

  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.

  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.

  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.

  Close
  No Recall

  More Info
• Carilion Materials Management
  

  ×

  Rifampin | Carilion Materials Management

  

  ---

  Rifampin can be administered by the oral route (see ). INDICATIONS AND USAGE

  See for dosing information in patients with renal failure. CLINICAL PHARMACOLOGY

  Tuberculosis

  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day.

  Pediatric Patients: 10-20 mg/kg, not to exceed 600 mg/day.

  It is recommended that oral rifampin be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.

  Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (RIFATER manufactured by sanofi-aventisU.S. LLC) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.
  ®

  Following the initial phase, treatment should be continued with rifampin and isoniazid (RIFAMATE manufactured by sanofi-aventis U.S. LLC) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive. ®

  Meningococcal Carriers

  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.

  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.

  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.

  Preparation of Extemporaneous Oral Suspension

  For pediatric and adult patients in whom capsule swallowing is difficult or where lower doses are needed, a liquid suspension may be prepared as follows:

  Rifampin 1% w/v suspension (10 mg/mL) can be compounded using Simple Syrup (Syrup NF):

  1. Empty the contents of four Rifampin 300 mg capsules or eight Rifampin 150 mg capsules onto a piece of weighing paper.

  2. If necessary, gently crush the capsule contents with a spatula to produce a fine powder.

  3. Transfer the rifampin powder blend to a 4-ounce amber glass or plastic (high density polyethylene [HDPE], polypropylene, or polycarbonate) prescription bottle.

  4. Rinse the paper and spatula with 20 mL of syrup, and add the rinse to the bottle. Shake vigorously.

  5. Add 100 mL of syrup to the bottle and shake vigorously.

  This compounding procedure results in a 1% w/v suspension containing 10 mg rifampin/mL. Stability studies indicate that the suspension is stable when stored at room temperature (25 ± 3°C) or in a refrigerator (2-8°C) for four weeks. This extemporaneously prepared suspension must be shaken well prior to administration.

  Close
  No Recall

  More Info
• Fresenius Kabi Usa, Llc
  

  ×

  Rifampin | Fresenius Kabi Usa, Llc

  

  ---

  Rifampin for Injection, USP is administered by IV infusion (see INDICATIONS AND USAGE).

  See CLINICAL PHARMACOLOGY for dosing information in patients with renal failure.

  
  Tuberculosis

  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, IV

  Pediatric Patients: 10 to 20 mg/kg, not to exceed 600 mg/day, IV

  Rifampin is indicated in the treatment of all forms of tuberculosis.  A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., RIFATER®) is recommended in the initial phase of short-course therapy which is usually continued for 2 months.  The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low.  The need for a fourth drug should be reassessed when the results of susceptibility testing are known.  If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.

  Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE®) for at least 4 months.  Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.

  Preparation of Solution for IV Infusion
  

  Reconstitute the lyophilized powder by transferring 10 mL of sterile water for injection to a vial containing 600 mg of rifampin for injection.  Swirl vial gently to completely dissolve the antibiotic. The reconstituted solution contains 60 mg rifampin per mL and is stable at room temperature for 24 hours.  Prior to administration, withdraw from the reconstituted solution a volume equivalent to the amount of rifampin calculated to be administered and add to 500 mL of infusion medium. Mix well and infuse at a rate allowing for complete infusion within 3 hours.  Alternatively, the amount of rifampin calculated to be administered may be added to 100 mL of infusion medium and infused in 30 minutes.

  Dilutions in dextrose 5% for injection (D5W) are stable at room temperature for up to 4 hours and should be prepared and used within this time.  Precipitation of rifampin from the infusion solution may occur beyond this time.  Dilutions in normal saline are stable at room temperature for up to 24 hours and should be prepared and used within this time. Other infusion solutions are not recommended.

  Incompatibilities

  Physical incompatibility (precipitate) was observed with undiluted (5 mg/mL) and diluted (1 mg/mL in normal saline) diltiazem hydrochloride and rifampin (6 mg/mL in normal saline) during simulated Y-site administration.
  

  Meningococcal Carriers
  

  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.

  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.

  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.

  Close
  No Recall

  More Info
• Heritage Pharmaceuticals Inc.
  

  ×

  Rifampin | Heritage Pharmaceuticals Inc.

  

  ---

  
  

  Rifampin for Injection should be administered by IV infusion (see INDICATIONS AND USAGE).
  See CLINICAL PHARMACOLOGY for dosing information in patients with renal failure.
  
  Tuberculosis
  Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, IV
  Pediatric Patients: 10 to 20 mg/kg, not to exceed 600 mg/day, IV
  Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., RIFATER®) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.
  Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE®) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.
  Preparation of Solution for IV Infusion : Reconstitute the lyophilized powder by transferring 10 mL of sterile water for injection to a vial containing 600 mg of rifampin for injection. Swirl vial gently to completely dissolve the antibiotic. The reconstituted solution contains 60 mg rifampin per mL and is stable at room temperature for 24 hours. Prior to administration, withdraw from the reconstituted solution a volume equivalent to the amount of rifampin calculated to be administered and add to 500 mL of infusion medium. Mix well and infuse at a rate allowing for complete infusion within 3 hours. Alternatively, the amount of rifampin calculated to be administered may be added to 100 mL of infusion medium and infused in 30 minutes.
  Dilutions in dextrose 5% for injection (D5W) are stable at room temperature for up to 4 hours and should be prepared and used within this time. Precipitation of rifampin from the infusion solution may occur beyond this time. Dilutions in normal saline are stable at room temperature for up to 24 hours and should be prepared and used within this time. Other infusion solutions are not recommended.
  Incompatibilities : Physical incompatibility (precipitate) was observed with undiluted (5 mg/mL) and diluted (1 mg/mL in normal saline) diltiazem hydrochloride and rifampin (6 mg/mL in normal saline) during simulated Y-site administration.
  
  Meningococcal Carriers
  Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.
  Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.
  Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.

  Close
  No Recall

  More Info